Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Distal protection device submission

This article was originally published in The Gray Sheet

Executive Summary

Kensey Nash projects a July 510(k) submission for its TriActiv saphenous vein graft surgery distal protection device. The firm expects clearance this year, but no longer anticipates launching the system by the Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C. in September, as Kensey Nash previously stated in January. Former estimates were based on the assumption that a 510(k) based on the 894-patient PRIDE trial would be filed in April (1"The Gray Sheet" Jan. 26, 2004, p. 5)...
Advertisement

Related Content

TCT 2004 Highlights Peripheral Stenting, But DES Remains Hot Topic
Kensey Nash Extracts Biomaterials Growth To Curb Reliance On Angio-Seal
Kensey Nash Extracts Biomaterials Growth To Curb Reliance On Angio-Seal
Advertisement
UsernamePublicRestriction

Register

MT020502

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel